Advice
Following an abbreviated submission:
mercaptopurine 20mg/mL oral suspension (Xaluprine®) is accepted for use within NHS Scotland.
Indication under review: for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.
Mercaptopurine dosing is governed by cautiously monitoring haematotoxicity. The oral suspension and tablet formulations are not bioequivalent in terms of peak plasma concentrations and therefore careful haematological monitoring of the patient is advised on switching formulations.
Mercaptopurine oral suspension is more expensive than the tablet formulation.
Download detailed advice39KB (PDF)
Medicine details
- Medicine name:
- mercaptopurine (Xaluprine)
- SMC ID:
- 798/12
- Indication:
- For the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.
- Pharmaceutical company
- Nova Laboratories Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 13 August 2012